Split History
ETFs Holding ARNA »    ARNA Historical Stock Prices »
Video: What is a Stock Split?

If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Arena Pharmaceuticals is a biopharmaceutical company focused on delivering medicines with pharmacology and pharmacokinetics to patients globally. Co.'s clinical programs include: etrasimod (APD334), which Co. is evaluating in ulcerative colitis, and Crohn's disease, as well as a program for atopic dermatitis; olorinab (APD371), which is is being evaluated for a range of visceral pain conditions associated with gastrointestinal diseases and for treatment of abdominal pain associated with irritable bowel syndrome; APD418, which is being evaluated in a trial for acute heart failure; and Temanogrel, a compound in its cardiovascular therapeutic area. According to our ARNA split history records, Arena Pharmaceuticals has had 1 split.
ARNA split history picture
Arena Pharmaceuticals (ARNA) has 1 split in our ARNA split history database. The split for ARNA took place on June 19, 2017. This was a 1 for 10 reverse split, meaning for each 10 shares of ARNA owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 100 share position following the split.

When a company such as Arena Pharmaceuticals conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.

Looking at the ARNA split history from start to finish, an original position size of 1000 shares would have turned into 100 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Arena Pharmaceuticals shares, starting with a $10,000 purchase of ARNA, presented on a split-history-adjusted basis factoring in the complete ARNA split history. ARNA split adjusted history picture

Growth of $10,000.00
Without Dividends Reinvested

Start date: 06/24/2011
End date: 06/23/2021
Start price/share: $13.10
End price/share: $67.21
Dividends collected/share: $0.00
Total return: 413.05%
Average Annual Total Return: 17.75%
Starting investment: $10,000.00
Ending investment: $51,285.90
Years: 10.01
Date Ratio
06/19/20171 for 10
ARNA is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:

ARTC Split History
ARWR Split History
ASMB Split History
ASTM Split History
ASTX Split History
ATEC Split History
ATNM Split History
ATOS Split History
ATRC Split History
ATRI Split History

Also explore: ARNA shares outstanding history

Trisura Group Ltd. (TSU.CA)
BetaPro NASDAQ-100 2x Daily Bull ETF (HQU)
BetaPro S&P 500 2x Daily Bull ETF (HSU)
BetaPro S&P/TSX Capped Energy 2x Daily Bull ETF (HEU)
BetaPro S&P/TSX Capped Financials 2x Daily Bull ETF (HFU)
BetaPro S&P/TSX 60 2x Daily Bull ETF (HXU)
BetaPro Crude Oil Leveraged Daily Bull ETF (HOU)
Horizons Big Data & Hardware Index ETF (HBGD.U)
Horizons Big Data & Hardware Index ETF (HBGD)
Horizons NASDAQ-100 Index ETF (HXQ.U)
More latest stock splits »
Latest mega mergers »
Latest stock buybacks »

ARNA Insider Buying

ARNA Split History | www.SplitHistory.com | Copyright © 2013 - 2021, All Rights Reserved

Nothing in www.SplitHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.